Lectenz® Bio receives a U01 from the NIH Common Fund Glycoscience program to further develop GlycoSenseTM technology.

Lectenz® Bio receives an SBIR Phase I from the National Institute of General Medical Sciences (NIGMS) to develop additional Lectenz® specific for all N-Glycans.

NIGMS awards Lectenz® Bio a second SBIR Phase I to apply the GlycoSenseTM technology to monitoring glycoenzyme engineering reactions.